Asthma management typically aims at maintaining asthma control by using corticosteroids that suppress airway inflammation. However, acute asthma exacerbations often occur leading to loss of control and necessitating systemic corticosteroids, hospitalization, or even both. Consequently, acute asthma exacerbations have a major impact on the mortality and morbidity of asthma as well as on the medical costs associated with the disease [1]. Although the development of new medications to reduce the frequency and severity of acute asthma exacerbations has advanced recently, an incomplete understanding of the immuno-pathogenetic mechanisms underlying these episodes of spontaneous worsening still limits their development.
ABSTRACT
PUBLICATION RECORD
- Publication year
2015
- Venue
OncoTarget
- Publication date
2015-07-08
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-7 of 7 references · Page 1 of 1
CITED BY
Showing 1-5 of 5 citing papers · Page 1 of 1